Editor’s Note: This article was updated March 6, 2020, with news of two more hospitals offering the NovoTTF-100L System for pleural mesothelioma.
Just eight months ago, the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100L System for treating pleural mesothelioma.
As of March 6, 2020, the humanitarian use device is now offered in nine hospitals covering eight states. Baylor St Luke’s Medical Center (Houston, Texas), which has a renowned mesothelioma program, is the newest addition to the list. The Houston, Texas-based hospital announced last week via press release that it would offer the “at-home” treatment to qualifying patients.
“We are always looking for treatments to improve the survival, quality of life, and options for patients with mesothelioma,” Dr. R. Taylor Ripley, the director of the hospital’s mesothelioma program, said in the press release. “NovoTTF-100L provides another therapeutic option that may be valuable. Therefore, we have added it to our treatment options.”
The NovoTTF-100L is a tumor treating fields device. It sends electrical shocks into the patient’s body, where the low-intensity currents attack mesothelioma cells and either slow the cancer’s growth or kill the disease. One of the major benefits of the NovoTTF-100L is it’s an at-home treatment, one patients can wear during their daily routine or even while sleeping.
Another benefit? Pleural mesothelioma patients don’t have to go too far to receive the new treatment. The eight states with hospitals offering the device cover every region of the United States except for the northeast:
West Cancer Clinic in Germantown, Tennessee, was the first hospital offering the treatment. It’s also the facility where the first mesothelioma patient received the treatment.
Aside from Baylor St. Luke’s and the West Cancer Clinic, the other seven hospitals offering the treatment are:
- Allegheny Health Network and Allegheny General Hospital (Pittsburgh, Pennsylvania)
- Beaumont Health System — Royal Oaks (Royal Oak, Michigan)
- Loyola University Medical Center (Maywood, Illinois)
- Miami Cancer Institute
- Ochsner Medical Center (New Orleans, Louisiana)
- Ochsner Health Center (Baton Rouge, Louisiana)
- Oregon Health and Science University (Portland)
If you’d like to learn more about the NovoTTF-100L System, speak with our medical staff. Our patient advocate and registered nurse, Jenna Campagna, can help you connect with one of the hospitals listed above. Please email her at email@example.com.
How the NovoTTF-100L Works
In May 2019, the FDA approved the NovoTTF-100L for frontline treatment in specific circumstances and only when combined with chemotherapy. According to Novocure, the developer of the device, the treatment is only approved for “locally advanced or metastatic malignant pleural mesothelioma” and solely for patients who can’t have surgery.
The device is a low-maintenance treatment that shouldn’t impede patients’ day-to-day lives. Dr. Uri Weinberg, who oversees the development and research activities at Novocure, talked about the NovoTTF-100L on a recent Mesothelioma Guide podcast.
“NovoCure has been working on Tumor Treating Fields for close to the past 20 years now,” Dr. Weinberg said. “Patients are using the NovoTTF-100L System … for at least 18 hours per day. “Patients are actually using the System during the day and night. … They can sleep, and the device operates.”
The most recent study involving the NovoTTF-100L involved 80 pleural mesothelioma patients. The median overall survival for participants using the device was 18.2 months. Around 62% of them lived for at least one year and 97% had disease control, meaning their cancer did not spread.
Show Sources & Author
- Find a treatment center. NovoTTF-100L System. Retrieved from:
https://www.novottf100l.com/find-a-treatment-center. Accessed: 01/31/2020.
- Mesothelioma Treatment Center offers new at-home device. Baylor College of Medicine. Retrieved from: https://www.bcm.edu/news/cancer/mesothelioma-treatment-center-new-device. Accessed: 02/12/2020.
If You Liked What You Read